[{"id":"a8c65941-392d-4c78-b64d-bcf83077b940","acronym":"","url":"https://clinicaltrials.gov/study/NCT02320292","created_at":"2021-01-18T11:00:10.127Z","updated_at":"2024-07-02T16:35:29.118Z","phase":"Phase 3","brief_title":"Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma","source_id_and_acronym":"NCT02320292","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2 • B2M","pipe":" | ","alterations":" BCL2 mutation","tags":["BCL2 • B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Zevalin (ibritumomab tiuxetan) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 02/11/2015","start_date":" 02/11/2015","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 11/09/2023","study_completion_date":" 11/09/2023","last_update_posted":"2023-11-15"}]